๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
NCT06883630Non-Small Cell Lung Cancer
DrugRC148
RemeGen Co., Ltd.
Phase 1
121
Beijing, Foshan, Guangzhou, Jiangmen, Gulin, Nanning, Harbin, Hanyang
2025-03-13
Recruiting
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
NCT06859515Wet Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd
Observational
42
Beijing
2025-03-13
Recruiting
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
NCT06798207Gynecological Tumors
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
170
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Meizhou, Qingyuan, Nanning
2025-03-13
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
60
Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai
2025-03-13
Recruiting
Study on the Accuracy of Determining the Responsible Vessel in Medium Vessel Occlusive Stroke Based on Multi-type CT Evaluation
NCT07347587Stroke
Xuanwu Hospital, Beijing
Observational
622
Beijing
2025-03-13
Recruiting
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019Alzheimer Disease
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
Managing Pregnancy Pain With Baduanjin Exercise
NCT07153653Pregnancy-related Low Back and Pelvic Pain, Pregnancy
Peking Union Medical College Hospital
Not applicable
84
Beijing
2025-03-13
Recruiting
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06800651ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Jemincare
Phase 2
135
Beijing
2025-03-13
Recruiting
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06855069Ovarian Cancer
DrugsHS-20089·Topotecan·Doxorubicin·Paclitaxel
Hansoh BioMedical R&D Company
Phase 3
468
Beijing
2025-03-13
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsVolrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Beijing, Chengdu, Harbin, Shanghai, Wuhan, Zhengzhou
2025-03-12
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Beijing, Chongqing, Shijiazhuang, Nanjing, Suzhou, Xi'an, Xianyang, Shanghai
2025-03-11
Recruiting
Establishment of a Longitudinal Cohort for Newborns With Low Apgar Scores at Birth
NCT06961123Low Apgar Scores
Peking University Third Hospital
Observational
600
Beijing
2025-03-11
Recruiting
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
NCT07318155Coronary Artery Disease (CAD), Peripheral Arterial Disease
Sirius Therapeutics Co., Ltd.
Phase 2
104
Beijing
2025-03-11
Recruiting
Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease
NCT06741839Pleural Diseases, Pleural Effusion
China-Japan Friendship Hospital
Not applicable
158
Beijing
2025-03-11
Not yet open
Therapeutic Effect of Upadacitinib in Primary Sjรถgren's Syndrome
NCT06862284Primary Sjรถgren's Syndrome (pSS)
Peking University People's Hospital
Phase 2
30
Beijing
2025-03-10
Not yet open
Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients
NCT06857786Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Peking University
Phase 1
48
Beijing, Nanjing
2025-03-10
Recruiting
A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis
NCT06887127Rheumatoid Arthritis
DrugTLL-018
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase 3
350
Beijing
2025-03-10
Recruiting
The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease
NCT06871839Alzheimer's Disease, Lecanemab, Functional Magnetic Resonance Imaging
Cuibai Wei๏ผŒClinical Professor
Observational
120
Beijing
2025-03-10
Recruiting
Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping
NCT06819657Subarachnoid Hemorrhage, Aneurysmal, Cerebrovascular Disorders, Brain Diseases, Stroke
Beijing Tiantan Hospital
Not applicable
40
Beijing
2025-03-10
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Recruiting
Study of YK012 in Primary Membranous Nephropathy
NCT06982729Primary Membranous Nephropathy
DrugYK012
Excyte Biopharma Ltd
Phase 1
72
Beijing
2025-03-08
Recruiting
Electroacupuncture Treatment for Discogenic Low Back Pain
NCT06703671Discogenic Low Back Pain
Beijing Hospital
Not applicable
240
Beijing
2025-03-08
Active, closed
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
NCT06762080Leptomeningeal Metastasis
DrugsCadonilimab·Pemetrexed
Guangzhou Medical University
Phase 1/2
36
Huizhou, Beijing, Shanghai
2025-03-07
Recruiting
Carotid Endarterectomy and Stenting Timing
NCT06898151Carotid Endarterectomy, Carotid Stenting
Xuanwu Hospital, Beijing
Not applicable
268
Beijing
2025-03-07
Recruiting
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
NCT06844474NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
300
Beijing
2025-03-07
Not yet open
A Trial to Evaluate KPC000154 Tablets in Healthy Subjects
NCT06867406Healthy Subjectsใ€Lipid Metabolism
Kunming Pharmaceuticals, Inc.
Phase 1
92
Beijing
2025-03-07
Recruiting
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
NCT06796699Advanced Solid Tumors With MTAP Gene Deletion
Suzhou Genhouse Bio Co., Ltd.
Phase 1
90
Beijing, Shanghai, Taiyuan
2025-03-07
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Active, closed
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
NCT06855758Kidney Transplant, Delayed Graft Function, Intraoperative Hypotension
DrugTerlipressin
Beijing Friendship Hospital
Not applicable
150
Beijing
2025-03-06
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
Metformin Hydrochloride Sustained-release Tablets (โ…ข) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease
NCT06932874Atherosclerotic Heart Disease, Type 2 Diabetes
China National Center for Cardiovascular Diseases
Phase 4
356
Beijing
2025-03-04
Recruiting
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
NCT06541639Advanced or Recurrent Solid Tumors
DrugTislelizumab
Peking University
Phase 1
78
Beijing, Shanghai
2025-03-04
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Recruiting
Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System
NCT06783049Ischemic Stroke, Transient Ischemic Attack (TIA)
Beijing Tiantan Hospital
Not applicable
4,490
Beijing, Shihezi
2025-03-03
Recruiting
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
NCT07275736Neurological Autoimmune Diseases
Juventas Cell Therapy Ltd.
Phase EARLY_PHASE1
18
Beijing
2025-03-01
Recruiting
Study of SYH2062 Injection in Healthy Chinese Volunteers
NCT06842537Healthy Chinese Volunteers
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1
46
Beijing
2025-03-01
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Ivonescimab
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
NCT06864975Hemophilia a with Inhibitor
Runhui WU
Phase 4
110
Beijing
2025-03-01
Recruiting
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
NCT06839547Advanced Breast Cancer Brain Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
100
Beijing
2025-03-01
Recruiting
Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
NCT06849167Non-Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2
63
Beijing
2025-03-01
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
By invitation
Comparative Study of Rotational Cryobiopsy Needle and Automated Biopsy Needle in Transthoracic Biopsy Diagnosing Peripheral Pulmonary Lesions
NCT07772479Peripheral Pulmonary Lesions (PPLs), Pulmonary Nodules
Beijing Chao Yang Hospital
Not applicable
308
Beijing
2025-03-01
Recruiting
Trop-2 Targeted PET Probes in Advanced TNBC
NCT07046455TNBC - Triple-Negative Breast Cancer
Peking University Cancer Hospital & Institute
Not applicable
20
Beijing
2025-03-01
Not yet open
Allogeneic B7H3 CAR-ฮณฮดT Cell Therapy for Advanced Solid Tumors
NCT06825455Advanced Solid Tumors, Ovarian Cancers, Peritoneal (metastatic) Cancer
DrugsFludarabine·Cyclophosphamide
Peking University
Phase EARLY_PHASE1
18
Beijing
2025-03-01
Recruiting
Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis
NCT07801638Cerebral Venous Thrombosis
DrugTocilizumab
Capital Medical University
Not applicable
80
Beijing
2025-03-01
Recruiting
Yishen Shujin Decoction for Fibromyalgia Syndrome
NCT07555691Fibromyalgia Syndrome
Juan Jiao
Not applicable
100
Beijing
2025-03-01
Not yet open
Effect of Squash Exercise Intervention on Sleep and Mental Health Among Young Adults
NCT06839417Sleep, Mental Health, Exercise
Tsinghua University
Not applicable
100
Beijing
2025-03-01
Not yet open
A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)
NCT06847607AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
DrugIptacopan
Bing Han
Not applicable
20
Beijing
2025-03-01
Recruiting
Acupuncture for Prediabetes With Combined Obesity
NCT06359418Obesity, Abdominal Obesity, PreDiabetes
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
260
Beijing
2025-03-01
Not yet open
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
NCT06775093Polycystic Ovary Syndrome, Obesity, Infertility, Female
DrugMetformin
Peking University Third Hospital
Not applicable
392
Beijing
2025-03-01
Recruiting
Clinical Application of CAIX-Targeted PET Imaging in Tumors
NCT07590310Kidney Cancers
Peking University Cancer Hospital & Institute
Phase EARLY_PHASE1
3
Beijing
2025-03-01
Recruiting
Comparison of Physiological Effects of Two High-Flow Tracheal Oxygen Versus T-Piece During Spontaneous Breathing Trials
NCT06816706Critical Care, Oxygen Therapy, Mechanical Ventilation
Jian-Xin Zhou
Not applicable
20
Beijing
2025-03-01
Recruiting
Clinical Analgesic Management in Dementia
NCT07323914Alzheimer Disease
Xuanwu Hospital, Beijing
Phase 3
10
Beijing
2025-03-01
Recruiting
Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency.
NCT07236788Obesity, Anemia, Iron Deficiencies, Bariatric Surgery
China-Japan Friendship Hospital
Not applicable
200
Beijing
2025-03-01
Recruiting
rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage
NCT06814964Intraventricular Hemorrhage
Beijing Tiantan Hospital
Phase 1
18
Beijing
2025-03-01
Not yet open
Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol
NCT06845254Acute Coronary Syndrome
DrugXuesaitong soft
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 3
400
Beijing
2025-03-01
Recruiting
Electroencephalogram Predicts Post-operative Delirium
NCT06894238Neurosurgery, Delirium - Postoperative, Brain Tumor Adult
Beijing Sanbo Brain Hospital
Observational
137
Beijing
2025-03-01
Recruiting
Kahook Dual Blade Goniotomy in Chronic Primary Angle-Closure Glaucoma
NCT07517302Primary Angle-closure Glaucoma
Peking University People's Hospital
Not applicable
68
Beijing
2025-03-01
Active, closed
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
NCT06924424Multiple Myeloma, Neoplasms
Peking University People's Hospital
Not applicable
105
Beijing, Zhengzhou
2025-03-01
Recruiting
The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
NCT06861543Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 1
18
Beijing
2025-03-01
Recruiting
Assessing the Performance of GPT-4o in Evaluating the Safety of Home Environment for Older Adults
NCT06962696Elderly (People Aged 65 or More), Home Environment Related Disease
Peking University Third Hospital
Observational
20
Beijing
2025-03-01
Recruiting
The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study
NCT06844643Axial Spondyloarthritis, Ankylosing Spondylitis (AS)
China-Japan Friendship Hospital
Observational
2,250
Beijing
2025-03-01
Recruiting
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
NCT06826430Autoimmune Thrombocytopenia
Juventas Cell Therapy Ltd.
Phase 1
12
Beijing
2025-03-01
Active, closed
Transvaginal Electromechanical Fragmentation and Removal of Large Uterus in a Sealed Bag: The First Group of Clinical Studies Balancing Scar - Free and Anti - Dissemination
NCT07486622Uterine Fibroids, Adenomyosis, Enlarged Uterus
Chang Zhou
Observational
25
Beijing
2025-03-01
Recruiting
Investigation of Tetralogy of Fallot in Neonates
NCT06822400Tetralogy of Fallot (TOF), Pulmonary Stenosis, Ventricular Septal Defects (VSD), Double Outlet Right Ventricle
Beijing Anzhen Hospital
Not applicable
160
Beijing
2025-03-01
Recruiting
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
NCT06839560Brain Metastasis From Advanced HER2-negative Breast Cancer
DrugsConcurrent Radiotherapy·Adebrelimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
102
Beijing
2025-03-01
Not yet open
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
NCT06861777Esophageal Squamous Cell Carcinoma (ESCC)
YIN LI
Phase 2/3
474
Beijing
2025-03
Not yet open
A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy
NCT06858852Gastroscopy, Colonoscopy
Ahon Pharmaceutical Co., Ltd.
Phase 3
270
Beijing, Shenzhen, Chengdu, Guangyuan, Yibin
2025-03
Recruiting
KPD Consolidation After ASCT in NDMM Patients
NCT06879379Multiple Myeloma, Newly Diagnosed
Peking University People's Hospital
Phase 2/3
202
Beijing, Shanghai
2025-03
Not yet open
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931Systemic Lupus Erythematosus
DrugTQB3702
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Recruiting
Efficacy and Safety of Photodynamic Therapy for Cervical and Vaginal Intraepithelial Neoplasia
NCT06982976Precancerous Cervical Lesion
Peking University Third Hospital
Not applicable
250
Beijing
2025-02-28
Recruiting
Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ
NCT06808971Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
61
Beijing
2025-02-28
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
9
Beijing
2025-02-28
Not yet open
Familial Breast Cancer in China
NCT06833216Breast Carcinoma, Genetic Variation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Beijing, Lanzhou, Wuhan, Yantai, Chengdu, Kunming
2025-02-28
Recruiting
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
NCT06773312Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Phase 1
80
Beijing
2025-02-28
Not yet open
Effect of Food-derived Active Components on Digestive Tract Health in Adults with Irritable Bowel Syndrome
NCT06779214Irritable Bowel Syndrome - Diarrhoea
Peking University
Not applicable
180
Beijing
2025-02-28
Not yet open
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
NCT06485232Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1
25
Beijing
2025-02-28
Recruiting
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
NCT06696261Postprandial Distress Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
342
Beijing, Lanzhou, Guiyang, Shijiazhuang, Xingtai, Baoding, Luoyang, Changchun
2025-02-27
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
NCT06830343Overweight or Obesity
DrugWegovy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 1
66
Beijing
2025-02-27
Recruiting
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
NCT06666283Diabetic Kidney Disease
Alebund Pharmaceuticals
Phase 1
18
Beijing
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Recruiting
Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
NCT06862700Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Vasopressors, Hemodynamic Management
Xiaotong Hou
Observational
534
Beijing
2025-02-26
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT06873659Solid Tumor, Gastric Cancer, Liver Cancer
Qurgen Inc.
Phase 1
96
Beijing, Lanzhou, Guangzhou, Nanjing, Xi'an, Jinan, Shanghai, Hangzhou
2025-02-26
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
DrugTarlatamab
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
NCT06779136Prurigo Nodularis
Shanghai Mabgeek Biotech.Co.Ltd
Phase 3
160
Beijing
2025-02-26
Recruiting
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT07051811Essential Hypertension
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
NCT06869239Limited-stage Small Cell Lung Cancer (LS-SCLC)
DrugsCisplatin/carboplatin·Etoposide
Peking University Cancer Hospital & Institute
Observational
65
Beijing
2025-02-25
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
Phase I Study of OriC902 in Treatment of Advanced HCC
NCT06891742HCC
Peking University
Phase 1
44
Beijing
2025-02-24
Recruiting
An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
NCT06913725Brain Arteriovenous Malformations
DrugFCN-159
Xuanwu Hospital, Beijing
Phase 2
10
Beijing
2025-02-24
Not yet open
Effects of Exercise Snacks and Sprint Interval Training in Overweight Adults
NCT06849453Cardiovascular Function, Cardiorespiratory Fitness
Beijing Sport University
Not applicable
45
Beijing
2025-02-24
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297Melanoma
DrugsIBI363·Pembrolizumab
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Rows per page Showing 2501–2600 of 5484
Previous 24 25 26 27 28 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=26

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.